Skip to main content
OpenTrials
Completed

NCT Number: NCT03239691

A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients

The main study objective is to assess the effect of ACT-709478 in male and female subjects with photosensitive epilepsy following single dose administration

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

HOSP - Bicêtre Neurologie, Le Kremlin-Bicêtre, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent in the local language prior to any study-mandated procedure
  • Male and female subjects aged between 18 and 60 years (inclusive) at screening
  • Photosensitive epilepsy and a generalized PPR in response to IPS of at least 4 units on a SPR in at least 1 condition (eye closure, eyes closed, or eyes open) on 2 occasions at screening with at least 1 hour interval and reproducible on Day -1 (less than 3 units difference in SPR between screening and Day -1)
  • Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests
  • Women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use a reliable method of contraception with a failure rate of <1% per year, be sexually inactive, or have a vasectomized partner. Hormonal contraceptives must be initiated at least 1 month before first study treatment administration

Exclusion criteria

  • Lactating women
  • Known hypersensitivity to any of the excipients of the study treatment formulation
  • History or clinical evidence of any disease other than epilepsy and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism, or excretion of the study treatment (appendectomy and herniotomy allowed, cholecystectomy not allowed)
  • Relevant history of a suicide attempt or suicidal behavior. Any recent suicidal ideation within the last 6 months (categories 4 or 5), or any suicidal behavior within the last 2 years, except for "Non-Suicidal Self-Injurious Behavior" (item also included in the Suicidal Behavior section), as judged by the investigator using the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening
  • History of status epilepticus during the last 12 months
  • History of non-epileptic seizures that cannot be differentiated from the participant's epileptic seizures
  • History of generalized tonic-clonic seizures triggered by IPS
  • Previous history of repeated fainting, syncope, orthostatic hypotension, or vasovagal reactions in the past 5 years
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol

Treatment and study plan

ACT-709478 for oral use

Drug

Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg

Placebo

Drug

Matching placebo available as matching capsules for oral administration

Primary outcomes

  1. Individual evaluation of the response to intermittent photic stimulation

    Time frame: From Day 2 to Day 10

    Positive response described as complete suppression of photoparoxysmal response (PPR) or a clinically relevant reduction in the standardized photosensitive range (SPR)

Secondary outcomes

  1. Time to onset of positive response

    Time frame: From Day 2 to Day 10

    Defined by the first time point after ACT-709478 administration at which complete suppression of PPR or clinically relevant reduction in SPR is achieved

  2. Duration of positive response

    Time frame: From Day 2 to Day 10

    Defined as the time elapsed between the time point of onset of the positive response and the last time point of the positive response after ACT-709478 administration

  3. Maximum SPR reduction

    Time frame: From Day 2 to Day 10

    Defined as the largest reduction in SPR achieved at any time point compared to baseline during the positive response after ACT-709478 administration

  4. Time to maximum SPR reduction

    Time frame: From Day 2 to Day 10

Sponsors and collaborators

Lead sponsor

Idorsia Pharmaceuticals Ltd.

Industry

Registry information

Official study title

A Phase 2a, Multi-center, Single-blind, Within-subject, Placebo-controlled Study to Assess the Pharmacodynamics of ACT-709478 in Subjects With Photosensitive Epilepsy

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Aug 4, 2017
Registry last updated
Aug 31, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.